The CEO of Inovio Pharmaceuticals is Exercising Options

By Carrie Williams

Today, the CEO of Inovio Pharmaceuticals, Jong Joseph Kim, exercised options of Inovio Pharmaceuticals for $1.08M.

In addition to Jong Joseph Kim, one other INO executive reported Sell trades in the last month.

The company has a one-year high of $9.86 and a one-year low of $3.76. Currently, Inovio Pharmaceuticals has an average volume of 868.6K.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $11.67, reflecting a -56.6% downside.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.